Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 11;11(3):ofad694. doi: 10.1093/ofid/ofad694

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 1. — Antithyroglobulin antibodies (A) and thyroperoxidase antibodies (B) over time for each participant. Participant (Pt) #1 and Pt #2 received 2 doses of cemiplimab. Pt #3 and #4 received a single dose of cemiplimab due to suspected adverse events. Pt #5 received 1 placebo dose. Pt #3 (shown in blue, thyroiditis immune-related adverse event [AE]) had a detectable pretreatment antithyroglobulin antibody level and thyroperoxidase antibody level with an increase in both measures after cemiplimab infusion. Alanine aminotransferase (ALT; C) and aspartate aminotransferase (AST; D) over time for each participant. Pt #4 (shown in green, liver injury AE) experienced increased AST and ALT at week 2. Elevated AST and ALT (grade 1–2) recurred for this participant at weeks 20, 29, and 48, attributed to ongoing alcohol use.